Avodart belongs to a class of drugs called 5-alpha-reductase inhibitors, which inhibit the conversion of testosterone into dihydrotestosterone (DHT). Propecia (finasteride) also belongs to this group. However, Avodart is more effective and quicker-acting than Propecia because it inhibits both forms of 5-alpha-reductase, whereas Propecia inhibits one.

Uses

While Avodart is officially approved, and most commonly used, to treat enlargement of the prostate gland, it may also be used to treat male pattern baldness. While clinical trials for Avodart as a hair loss drug were called off in late 2002, it can still be prescribed for "off-label" purposes by physicians, and an increasing number are willing to do so.

The reason the trials were called off is not outwardly known. However, industry sources speculate that Avodart would have been seen as too similar to Propecia to have proved profitable as a hair loss treatment.

Read more at Wikipedia.org

• [List your site here Free!]



	FDA approvals - Avodart, Subutex, Suboxone Dutasteride. The U.S. Food and Drug Administration (FDA) approved dutasteride (Avodart) for the treatment of symptomatic benign prostatic hyperplasia ... From American Family Physician, 11/15/02 by Carrie Morantz

	Combination therapy for prostate trouble For men with enlargement of the prostate gland, also called benign prostatic hyperplasia (BPH), combining two classes of drugs reduces the risk of significant ... From Nutrition Health Review, 6/22/04

	Pipeline previews Abbreviated New Drug Application (ANDA) 76-329 Approval date: 11/6/02 Name: Amcinonide Lotion USP, .1% Type: Generic approval for Cyclocort Applicant: Altana, Inc. OTC/RX status: RX Ind From Journal of Drugs in Dermatology, 4/1/03

	Avodart Now Available by Prescription for Treatment of Benign Prostatic Hyperplasia, BPH, Common Condition in Men over 50 Business Editors RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan. 14, 2003 Avodart Arrests Disease Process and Provides Long-Term Approach for ... From Business Wire, 1/14/03

	FDA Approves GlaxoSmithKline's Avodart, The First Dual-Acting 5 Alpha-Reductase Inhibitor for Benign Prostatic Hyperplasia, BPH Business Editors RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct. 10, 2002 Avodart Improves Symptoms and Reduces Risk of Acute Urinary Retention ... From Business Wire, 10/10/02

	Never mind the performance targets - can GSK and Garnier deliver the Jean-Pierre Garnier, the chief executive of GlaxoSmithKline, will probably not sleep well tonight. Tomorrow, the drugs company will hold its annual ... From Independent on Sunday, The, 5/16/04 by Tim Webb

	2 efforts emerge to further prostate cancer fight 2 efforts emerge to further prostate cancer fight By MARILYNN MARCHIONE mmarchione@journalsentinel.com, Journal Sentinel Monday, October 20, 2003 Recent news that a drug can lower a man's From Milwaukee Journal Sentinel, The, 10/20/03 by MARILYNN MARCHIONE

	GlaxoSmithKline Presents Rapidly Expanding Pipeline of Oncology and Supportive Care Compounds PHILADELPHIA and LONDON, Nov. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc today updated investors and financial analysts in New York on the Company's ... From PR Newswire, 11/30/05

Home

Contact

Resources

Exchange Links

ebay